Status: One Wales interim decision | ||
Using the agreed starting and stopping criteria, ustekinumab (Stelara®▼) can be made available within NHS Wales for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response, non-response or intolerance to anti-TNF therapies and vedolizumab; for Crohn’s disease following loss of response, non-response or intolerance to anti-TNF therapies. The risks and benefits of the off-label use of ustekinumab (Stelara®▼) for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. In February 2023 OWMAG recommended this treatment in NHS Wales, in April 2024 there was a review of the recommendation. OWMAG found nothing new that affects the original decision. Next review: this advice will be reviewed after 2 years or earlier if new evidence becomes available. |
||
|
||
Medicine details |
||
Medicine name | ustekinumab (Stelara®) | |
Formulation | infusion | |
Reference number | OW25 | |
Indication | Treatment of inflammatory bowel disease in children and young people aged 6 to 17 years |
|
Company | Janssen-Cilag Ltd | |
BNF chapter | Gastro-intestinal system | |
Submission type | One Wales | |
Status | One Wales interim decision | |
Advice number | OW25 | |
Date of issue | April 2023 | |
Date of last review | May 2024 |